ReviewCurrent urology reports2003
Muscarinic receptors: what we know.
Review in Current urology reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 38 citations in OpenAlex.
- MIST1, an Inductive Signal for Salivary Amylase in Mesenchymal Stem Cells.International journal of molecular sciences · 2019Article
- Update on the management of overactive bladder: patient considerations and adherence.Open access journal of urology · 2010Review
- Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.Patient preference and adherence · 2008Article
- Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects.Current urology reports · 2007Review
- [Characteristic changes in the pattern of distribution of muscarinic receptors in the exstrophic bladder wall].Der Urologe. Ausg. A · 2007Article
- The puzzle of overactive bladder: controversies, inconsistencies, and insights.International urogynecology journal and pelvic floor dysfunction · 2006Review
- Management of overactive bladder with transdermal oxybutynin.Reviews in urology · 2006Article
- The Q-T interval and antimuscarinic drugs.Current urology reports · 2005Review
- Inhibition of ligand binding to G protein-coupled receptors by arachidonic acid.Journal of molecular neuroscience : MN · 2005Article
- Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.Current urology reports · 2004Review
- Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.Drugs · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An understanding of muscarinic receptors is tantamount to an understanding of overactive bladder. The M(3) muscarinic receptor subtype is responsible for detrusor smooth muscle contraction and it exerts an exocrine function in the salivary glands. Alterations in the receptor's response to acetylcholine as a result of injury may lead to hypersensitivity and overactivity. The M(2) receptor subtype, which is mainly responsible for cardiac function, is the muscarinic receptor of highest proportion in the detrusor. M(2) also may play a role in detrusor contraction in injury and pathologic states. Muscarinic antagonists are the mainstay of pharmacotherapy for overactive bladder, but those that are available are not tissue specific. Growing knowledge of the nuances of receptor-ligand behavior and interaction between muscarinic receptors subtypes may provide novel targets for future drug development, improve efficacy, and reduce bothersome side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.